ArticleUpdates in surgery2026
Single-port robotic areolar surgery for thyroid and neck procedures: a 3-year, 500-case single-surgeon experience using the da-Vinci SP system.
Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The single-port robotic areolar approach (SPRA) is a novel remote-access robotic technique using the da Vinci SP system. This study evaluated the feasibility and perioperative safety of SPRA in a large consecutive single-surgeon series and described its procedural spectrum. We retrospectively reviewed 500 consecutive SPRA procedures performed between December 2022 and January 2026. Primary outcomes were perioperative feasibility and safety, including operative variables, vocal cord outcomes, short-term biochemical parathyroid outcomes, and postoperative complications Secondary outcomes included procedural spectrum, including MRND, reoperative surgery, and parathyroidectomy, as well as lymph node yield and short-term serum thyroglobulin values after thyroid cancer surgery. The mean age was 43.1 ± 11.3 years, and 94.8% of patients were female. Lobectomy, total thyroidectomy, total thyroidectomy with MRND, reoperative procedures, and parathyroidectomy were performed in 384 (76.8%), 79 (15.8%), 15 (3.0%), 11 (2.2%), and 10 patients (2.0%), respectively. Transient and permanent vocal cord palsy occurred in 0.6% and 0.2%, respectively. Among total-thyroidectomy-status patients, early postoperative biochemical hypoparathyroidism and persistent early biochemical hypoparathyroidism at 2 weeks were observed in 19.8% and 6.6%, respectively. MRND yielded 31.16 ± 12.71 retrieved and 8.74 ± 5.43 metastatic lymph nodes. At 3 months, 78 of 86 measured patients (90.7%) had unstimulated thyroglobulin < 1.0 ng/mL. SPRA was feasible and showed acceptable perioperative safety in this large consecutive single-surgeon experience. MRND, reoperative surgery, and parathyroidectomy suggest technical expandability, but longer follow-up and multicenter studies are required to evaluate reproducibility and long-term oncologic outcomes.
Indexed as
Identifiers
42536310What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.